Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 751 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
LY3023414, Necitumumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Chandler, Arizona • Englewood, Colorado + 10 more
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Conditions
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung
Interventions
N17350
Biological
Lead sponsor
Onchilles Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 2 more
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
OGX-427, Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
16
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 13 more
Conditions
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions
NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Conditions
Non Squamous, Non-small-cell Lung Cancer
Interventions
Tivantinib, Placebo, Erlotinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
111
States / cities
Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Interventions
IO102-IO103 in combination with pembrolizumab
Drug
Lead sponsor
IO Biotech
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Duarte, California • Sacramento, California • San Diego, California + 6 more
Conditions
Non-small Cell Lung Cancer
Interventions
Canakinumab, Pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more
Conditions
Lung Cancer
Interventions
bevacizumab, vinorelbine tartrate
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, New York
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions
AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Santa Monica, California • Santa Rosa, California + 11 more
Conditions
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions
sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
106
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more
Conditions
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1150
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more
Conditions
Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
Interventions
Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
Conditions
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions
HC-7366
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Conditions
Non-Small Cell Lung Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more